Without a question, the two most significant biological targets for breast cancer are HER2 and CDK4/6. Anti-HER2 therapies improve overall survival, progression-free/disease-free survival, and objective response. Overall survival statistics are still pending, but three CDK4/6 inhibitors regularly increase progression-free survival and objective response. There is still a need for better endocrine therapies and chemotherapy optimisation. Particularly for triple-negative breast cancer, check point inhibitor-based immunotherapy in conjunction with chemotherapy is a promising area.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: